GlassScriptPhysician profile
Coy Allen
NPI 1346992401
$2,048.93
in general payments reported to CMS, 2019-2025
19 companies · $401 in 2025
The $401 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $372 · 2023: $407 · 2024: $869 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,677.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $665.05 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $261.91 | 2023-2024 | Verquvo, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $246.06 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $180.80 | 2022-2024 | Quviviq |
| Amgen INC. | $164.05 | 2023-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $137.44 | 2023-2025 | Jardiance, Emgality, Amyvid |
| Abbvie INC. | $78.94 | 2022-2025 | |
| Lexicon Pharmaceuticals, INC. | $67.33 | 2024 | Inpefa |
| Corcept Therapeutics | $54.80 | 2025 | Korlym |
| Axsome Therapeutics, INC. | $38.08 | 2024 | Auvelity |
| Janssen Biotech, INC. | $20.18 | 2022 | |
| Phathom Pharmaceuticals, INC. | $19.25 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.37 | 2024 | Xifaxan |
| Viatris Specialty LLC | $17.12 | 2025 | Yupelri |
| Astellas Pharma US INC | $17.10 | 2024 | Veozah |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $16.35 | 2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $16.04 | 2025 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.84 | 2025 | Caplyta |
| Mylan Specialty L.P. | $15.22 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Coy Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.